Key result
Early and long-term nonselective β-blockade with carvedilol reduced survival probability compared to control (88% vs 96%; P=0.03) and worsened left ventricular remodeling in rats with organic MR.
Why the study?
Does carvedilol improve left ventricular remodeling, function, and survival in a rat model of chronic organic mitral regurgitation?
RCT (n=87)
randomized
Does carvedilol improve left ventricular remodeling, function, and survival in a rat model of chronic organic mitral regurgitation?
Absolute Event Rate: 88% vs 96%
p-value: p=0.03
In a rat model of organic mitral regurgitation, early and long-term carvedilol administration worsened left ventricular remodeling, systolic function, and survival.
No takes yet. Share an insight, caveat, or question.
Raises caution for early carvedilol in organic MR; leaves open translation to human disease.
Pu et al. (2013) conducted an RCT in Chronic organic mitral regurgitation (n=87). Carvedilol vs. Control group was evaluated on Survival probability (p=0.03). Early and long-term nonselective β-blockade with carvedilol reduced survival probability compared to control (88% vs 96%; P=0.03) and worsened left ventricular remodeling in rats with organic MR.